Rapid Micro Biosystems (RPID) Financials

Rapid Micro Biosystems logo
$0.74 0.00 (-0.31%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$0.74 0.00 (-0.04%)
As of 11/19/2026 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Rapid Micro Biosystems

Annual Income Statements for Rapid Micro Biosystems

This table shows Rapid Micro Biosystems' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-45 -78 -61 -52 -47 -47
Consolidated Net Income / (Loss)
-37 -74 -61 -52 -47 -47
Net Income / (Loss) Continuing Operations
-37 -74 -61 -52 -47 -47
Total Pre-Tax Income
-37 -73 -61 -52 -47 -47
Total Operating Income
-31 -47 -63 -57 -50 -47
Total Gross Profit
-8.07 -7.74 -8.54 -5.49 -0.11 1.05
Total Revenue
16 23 17 23 28 34
Operating Revenue
16 23 17 23 28 34
Total Cost of Revenue
24 31 26 28 28 33
Operating Cost of Revenue
24 31 26 28 28 33
Total Operating Expenses
22 39 55 51 50 48
Selling, General & Admin Expense
9.98 18 27 25 22 23
Marketing Expense
5.96 12 15 13 13 12
Research & Development Expense
6.53 9.78 13 13 15 14
Total Other Income / (Expense), net
-6.40 -26 1.84 4.13 3.05 0.31
Interest Expense
6.36 5.71 -1.78 - 0.04 1.09
Interest & Investment Income
- - - 4.21 3.20 1.51
Other Income / (Expense), net
-0.05 -20 0.06 -0.08 -0.11 -0.11
Income Tax Expense
0.13 0.09 -0.58 0.03 0.02 0.04
Basic Earnings per Share
($126.11) ($3.94) ($1.43) ($1.22) ($1.08) ($1.05)
Weighted Average Basic Shares Outstanding
358.58K 19.78M 42.45M 43.02M 43.58M 44.68M
Diluted Earnings per Share
($126.11) ($3.94) ($1.43) ($1.22) ($1.08) ($1.05)
Weighted Average Diluted Shares Outstanding
358.58K 19.78M 42.45M 43.02M 43.58M 44.68M
Weighted Average Basic & Diluted Shares Outstanding
- 41.94M 42.19M 42.50M 43.24M 45.46M

Quarterly Income Statements for Rapid Micro Biosystems

This table shows Rapid Micro Biosystems' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-13 -13 -11 -9.67 -11 -12 -12 -12 -14 -13 -11
Consolidated Net Income / (Loss)
-13 -13 -11 -9.67 -11 -12 -12 -12 -14 -13 -11
Net Income / (Loss) Continuing Operations
-13 -13 -11 -9.67 -11 -12 -12 -12 -14 -13 -11
Total Pre-Tax Income
-13 -13 -11 -9.68 -11 -12 -11 -12 -14 -13 -11
Total Operating Income
-14 -13 -12 -10 -12 -12 -11 -12 -14 -12 -11
Total Gross Profit
-1.52 -0.19 0.62 0.98 0.40 0.28 0.70 -0.33 0.37 1.21 2.40
Total Revenue
5.61 6.62 7.60 8.22 7.21 7.26 7.84 11 8.00 8.05 9.53
Operating Revenue
5.61 6.62 7.60 8.22 7.21 7.26 7.84 11 8.00 8.05 9.53
Total Cost of Revenue
7.13 6.81 6.98 7.24 6.80 6.99 7.14 12 7.63 6.84 7.13
Operating Cost of Revenue
7.13 6.81 6.98 7.24 6.80 6.99 7.14 12 7.63 6.84 7.13
Total Operating Expenses
13 13 13 11 12 12 12 12 14 14 13
Selling, General & Admin Expense
5.63 5.82 5.68 4.83 5.69 6.08 5.64 5.34 7.44 6.77 6.33
Marketing Expense
3.28 3.63 3.38 2.98 2.75 3.11 2.90 3.32 3.42 3.44 3.02
Research & Development Expense
3.84 3.74 3.61 3.40 3.62 3.23 3.53 3.22 3.36 3.33 2.97
Restructuring Charge
- - - - - - 0.00 - - - 0.72
Total Other Income / (Expense), net
0.95 0.82 0.73 0.55 0.41 0.30 -0.13 -0.27 -0.42 -0.56 -0.61
Interest Expense
- - 0.01 - 0.01 0.01 0.39 - 0.64 0.65 0.63
Interest & Investment Income
0.98 0.84 0.78 - 0.47 0.35 0.35 0.35 0.26 0.14 0.10
Other Income / (Expense), net
-0.03 -0.02 -0.04 -0.02 -0.05 -0.04 -0.08 0.08 -0.03 -0.05 -0.07
Income Tax Expense
0.00 0.02 0.01 -0.01 0.01 0.01 0.01 0.01 0.01 0.05 0.02
Basic Earnings per Share
($0.31) ($0.29) ($0.26) ($0.22) ($0.26) ($0.27) ($0.26) ($0.26) ($0.31) ($0.27) ($0.23)
Weighted Average Basic Shares Outstanding
43.25M 43.62M 43.67M 43.58M 43.99M 44.65M 44.96M 44.68M 45.43M 48.35M 48.88M
Diluted Earnings per Share
($0.31) ($0.29) ($0.26) ($0.22) ($0.26) ($0.27) ($0.26) ($0.26) ($0.31) ($0.27) ($0.23)
Weighted Average Diluted Shares Outstanding
43.25M 43.62M 43.67M 43.58M 43.99M 44.65M 44.96M 44.68M 45.43M 48.35M 48.88M
Weighted Average Basic & Diluted Shares Outstanding
42.86M 42.91M 43.03M 43.24M 43.83M 44.21M 44.32M 45.46M 46.17M 50.16M 50.84M

Annual Cash Flow Statements for Rapid Micro Biosystems

This table details how cash moves in and out of Rapid Micro Biosystems' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
18 148 -151 -2.78 -7.29 3.04
Net Cash From Operating Activities
-31 -55 -59 -45 -44 -31
Net Cash From Continuing Operating Activities
-31 -55 -59 -45 -44 -31
Net Income / (Loss) Continuing Operations
-37 -74 -61 -52 -47 -47
Consolidated Net Income / (Loss)
-37 -74 -61 -52 -47 -47
Depreciation Expense
1.51 1.53 2.84 3.11 3.36 3.25
Non-Cash Adjustments To Reconcile Net Income
5.67 25 4.75 3.73 4.15 6.75
Changes in Operating Assets and Liabilities, net
-1.10 -8.00 -5.33 0.56 -4.77 6.06
Net Cash From Investing Activities
-16 -13 -93 42 37 14
Net Cash From Continuing Investing Activities
-16 -13 -93 42 37 14
Purchase of Property, Plant & Equipment
-0.69 -3.22 -6.74 -1.85 -1.37 -0.85
Purchase of Investments
-25 -25 -179 -62 -35 -27
Sale and/or Maturity of Investments
10 15 93 106 73 42
Net Cash From Financing Activities
64 217 0.69 0.15 0.20 20
Net Cash From Continuing Financing Activities
64 217 0.69 0.15 0.20 20
Repayment of Debt
-20 -28 - - 0.00 -0.88
Issuance of Debt
35 - - - 0.00 20
Issuance of Common Equity
0.00 165 0.73 0.19 0.24 1.10
Other Financing Activities, net
0.07 0.54 -0.03 -0.04 -0.04 -0.45
Cash Interest Paid
1.98 2.59 0.04 0.04 0.04 0.77

Quarterly Cash Flow Statements for Rapid Micro Biosystems

This table details how cash moves in and out of Rapid Micro Biosystems' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-1.85 15 -15 -5.05 2.00 -0.65 0.61 1.08 -6.22 0.87 -8.07
Net Cash From Operating Activities
-16 -10 -8.60 -9.91 -9.07 -9.70 -9.05 -3.25 -15 -13 -14
Net Cash From Continuing Operating Activities
-16 -10 -8.60 -9.91 -9.07 -9.70 -9.05 -3.25 -15 -13 -14
Net Income / (Loss) Continuing Operations
-13 -13 -11 -9.67 -11 -12 -12 -12 -14 -13 -11
Consolidated Net Income / (Loss)
-13 -13 -11 -9.67 -11 -12 -12 -12 -14 -13 -11
Depreciation Expense
0.81 0.83 0.86 0.87 0.85 0.81 0.80 0.79 0.71 0.67 0.65
Amortization Expense
- - - - 0.00 - - - 0.09 0.09 0.08
Non-Cash Adjustments To Reconcile Net Income
0.98 1.11 1.09 0.96 1.64 1.85 1.68 1.57 1.65 1.70 1.74
Changes in Operating Assets and Liabilities, net
-3.99 0.53 0.77 -2.08 -0.29 -0.51 -0.03 6.89 -3.22 -2.24 -4.76
Net Cash From Investing Activities
14 25 -6.54 4.86 11 9.34 -9.58 3.89 8.60 4.22 4.86
Net Cash From Continuing Investing Activities
14 25 -6.54 4.86 11 9.34 -9.58 3.89 8.60 4.22 4.86
Purchase of Property, Plant & Equipment
-0.59 -0.46 -0.22 -0.10 -0.32 -0.37 -0.07 -0.09 -0.39 0.22 -0.05
Purchase of Investments
-4.38 0.01 -25 -5.54 0.00 -2.29 -21 -4.02 -3.02 -2.00 0.01
Sale and/or Maturity of Investments
18 25 19 11 11 12 11 8.00 12 6.00 4.90
Net Cash From Financing Activities
0.16 -0.01 0.06 -0.01 0.38 -0.30 19 0.44 0.25 9.35 0.63
Net Cash From Continuing Financing Activities
0.16 -0.01 0.06 -0.01 0.38 -0.30 19 0.44 0.25 9.35 0.63
Repurchase of Common Equity
- - - - - - - - - - -0.41
Issuance of Common Equity
0.17 - 0.07 - 0.39 0.13 0.13 0.45 0.26 9.46 1.04
Other Financing Activities, net
-0.01 -0.01 -0.01 -0.01 -0.01 -0.43 -0.01 -0.01 -0.01 -0.01 -0.01
Cash Interest Paid
0.01 0.01 0.01 0.01 0.01 0.01 0.16 0.58 0.56 0.56 0.56

Annual Balance Sheets for Rapid Micro Biosystems

This table presents Rapid Micro Biosystems' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
70 241 191 143 98 75
Total Current Assets
62 218 139 120 81 61
Cash & Equivalents
30 178 27 24 17 20
Short-Term Investments
15 15 82 68 34 18
Accounts Receivable
4.99 5.01 5.37 5.53 7.52 3.13
Inventories, net
8.97 16 21 20 20 18
Prepaid Expenses
3.12 3.95 3.37 2.87 2.47 2.15
Plant, Property, & Equipment, net
7.05 11 14 13 11 8.97
Total Noncurrent Assets
0.10 12 38 10 6.06 4.71
Other Noncurrent Operating Assets
0.10 1.78 8.47 7.29 6.06 4.71
Total Liabilities & Shareholders' Equity
70 241 191 143 98 75
Total Liabilities
45 20 26 25 23 42
Total Current Liabilities
16 18 19 19 18 18
Accounts Payable
4.47 3.94 5.43 1.97 2.54 4.14
Accrued Expenses
6.65 11 8.15 9.91 7.22 8.32
Current Deferred Revenue
4.42 3.31 4.71 5.97 6.60 4.73
Other Current Liabilities
- 0.00 0.77 1.13 1.21 1.30
Total Noncurrent Liabilities
30 2.02 7.43 6.48 5.25 23
Long-Term Debt
25 - - - 0.00 19
Other Noncurrent Operating Liabilities
4.12 1.21 7.43 6.48 0.30 4.26
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-127 221 164 118 75 33
Total Preferred & Common Equity
-127 221 164 118 75 33
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-127 221 164 118 75 33
Common Stock
115 536 541 546 550 556
Retained Earnings
-242 -315 -376 -428 -475 -522
Accumulated Other Comprehensive Income / (Loss)
0.00 -0.02 -1.11 -0.10 0.04 0.01

Quarterly Balance Sheets for Rapid Micro Biosystems

This table presents Rapid Micro Biosystems' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
150 128 117 106 85 76 84 62 58 48
Total Current Assets
115 108 98 88 69 60 70 49 46 36
Cash & Equivalents
24 22 37 22 19 18 19 14 15 6.62
Short-Term Investments
66 57 32 39 23 13 22 9.13 5.08 0.10
Accounts Receivable
3.91 4.92 5.01 3.74 4.52 6.05 5.43 6.37 5.52 7.67
Inventories, net
20 20 21 21 21 21 21 17 19 20
Prepaid Expenses
1.56 3.29 2.37 2.11 2.27 2.28 2.21 2.46 2.06 2.27
Plant, Property, & Equipment, net
13 13 12 12 11 10 9.58 8.77 8.16 7.55
Total Noncurrent Assets
22 6.96 6.62 6.35 5.69 5.24 4.87 4.37 4.03 3.70
Other Noncurrent Operating Assets
7.63 6.96 6.62 6.35 5.69 5.24 4.87 4.37 4.03 3.70
Total Liabilities & Shareholders' Equity
150 128 117 106 85 76 84 62 58 48
Total Liabilities
22 22 22 21 20 21 40 42 41 39
Total Current Liabilities
16 16 17 16 15 16 17 19 18 17
Accounts Payable
3.27 1.16 2.18 2.33 2.64 3.33 3.59 4.67 5.18 4.82
Accrued Expenses
6.95 7.05 7.82 7.04 5.03 5.68 6.61 6.50 6.12 5.91
Current Deferred Revenue
4.56 6.23 5.43 5.36 6.09 6.14 5.07 6.63 5.51 4.41
Other Current Liabilities
0.84 1.15 1.17 1.19 1.24 1.26 1.28 1.32 1.34 1.37
Total Noncurrent Liabilities
6.76 6.19 5.90 5.55 4.95 4.64 24 23 23 22
Long-Term Debt
- - - - - - 19 19 19 19
Other Noncurrent Operating Liabilities
6.76 6.19 5.90 5.55 4.95 0.31 0.70 3.79 3.41 3.03
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
128 106 95 84 65 55 44 20 18 8.81
Total Preferred & Common Equity
128 106 95 84 65 55 44 20 18 8.81
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
128 106 95 84 65 54 44 20 18 8.81
Common Stock
545 548 549 550 552 553 554 557 567 570
Retained Earnings
-417 -442 -454 -466 -487 -498 -510 -537 -550 -561
Accumulated Other Comprehensive Income / (Loss)
-0.45 -0.08 -0.03 0.08 0.01 -0.00 0.01 -0.00 -0.00 0.00

Annual Metrics And Ratios for Rapid Micro Biosystems

This table displays calculated financial ratios and metrics derived from Rapid Micro Biosystems' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 41,352,523.00 41,994,285.00 42,398,905.00 - 44,322,555.00
DEI Adjusted Shares Outstanding
0.00 41,352,523.00 41,994,285.00 42,398,905.00 - 44,322,555.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -1.89 -1.45 -1.24 - -1.06
Growth Metrics
- - - - - -
Revenue Growth
0.00% 44.50% -26.25% 31.44% 24.57% 19.74%
EBITDA Growth
0.00% -127.65% 8.87% 11.24% 12.84% 5.18%
EBIT Growth
0.00% -121.42% 6.74% 10.31% 11.68% 5.05%
NOPAT Growth
0.00% -54.66% -33.85% 10.53% 11.75% 5.06%
Net Income Growth
0.00% -98.30% 17.30% 13.71% 10.63% -0.50%
EPS Growth
0.00% 96.88% 63.71% 14.69% 11.48% 2.78%
Operating Cash Flow Growth
0.00% -77.33% -6.52% 23.00% 2.06% 29.65%
Free Cash Flow Firm Growth
0.00% 0.00% -12.30% 29.69% 0.95% 58.03%
Invested Capital Growth
0.00% 354.04% 46.89% -10.52% 6.93% -53.30%
Revenue Q/Q Growth
0.00% 0.00% -4.64% 9.55% 7.19% 10.04%
EBITDA Q/Q Growth
0.00% 0.00% -3.93% 8.54% 4.17% -4.63%
EBIT Q/Q Growth
0.00% 0.00% -4.45% 8.21% 3.76% -4.12%
NOPAT Q/Q Growth
0.00% 0.00% -4.47% 8.23% 3.78% -4.36%
Net Income Q/Q Growth
0.00% 0.00% -3.12% 9.14% 3.11% -6.39%
EPS Q/Q Growth
0.00% 0.00% -102.67% 9.63% 3.57% -3.96%
Operating Cash Flow Q/Q Growth
0.00% -16.33% 2.06% 4.57% -0.94% 17.66%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 2.96% -1.28% 49.03%
Invested Capital Q/Q Growth
0.00% 0.00% -10.99% -3.17% 4.58% -46.70%
Profitability Metrics
- - - - - -
Gross Margin
-50.20% -33.32% -49.85% -24.36% -0.39% 3.12%
EBITDA Margin
-180.87% -284.93% -352.09% -237.76% -166.37% -131.75%
Operating Margin
-189.96% -203.31% -368.99% -251.18% -177.96% -141.10%
EBIT Margin
-190.25% -291.52% -368.65% -251.55% -178.36% -141.43%
Profit (Net Income) Margin
-230.63% -316.48% -354.91% -232.99% -167.16% -140.30%
Tax Burden Percent
100.36% 100.12% 99.06% 100.06% 100.05% 100.09%
Interest Burden Percent
120.78% 108.43% 97.18% 92.57% 93.68% 99.12%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-554.12% -309.36% -204.65% -162.42% -146.68% -152.93%
ROIC Less NNEP Spread (ROIC-NNEP)
-479.22% -273.30% -194.97% -151.39% -130.28% -110.12%
Return on Net Nonoperating Assets (RNNOA)
404.73% 249.53% 173.07% 125.23% 98.18% 66.11%
Return on Equity (ROE)
-149.39% -59.82% -31.58% -37.19% -48.50% -86.82%
Cash Return on Invested Capital (CROIC)
0.00% -437.16% -242.63% -151.32% -153.38% -80.27%
Operating Return on Assets (OROA)
-43.70% -43.53% -29.25% -33.91% -41.41% -54.91%
Return on Assets (ROA)
-52.97% -47.26% -28.16% -31.41% -38.81% -54.47%
Return on Common Equity (ROCE)
764.43% -22.87% -31.58% -37.19% -48.50% -86.51%
Return on Equity Simple (ROE_SIMPLE)
29.19% -33.27% -37.04% -44.47% -62.23% 0.00%
Net Operating Profit after Tax (NOPAT)
-21 -33 -44 -40 -35 -33
NOPAT Margin
-132.97% -142.31% -258.29% -175.83% -124.57% -98.77%
Net Nonoperating Expense Percent (NNEP)
-74.90% -36.06% -9.68% -11.03% -16.40% -42.81%
Return On Investment Capital (ROIC_SIMPLE)
- - - -33.56% -46.37% -63.66%
Cost of Revenue to Revenue
150.20% 133.32% 149.85% 124.36% 100.39% 96.88%
SG&A Expenses to Revenue
62.05% 77.03% 156.53% 110.73% 78.24% 67.75%
R&D to Revenue
40.62% 42.10% 75.09% 56.93% 52.04% 40.50%
Operating Expenses to Revenue
139.76% 169.99% 319.14% 226.82% 177.57% 144.22%
Earnings before Interest and Taxes (EBIT)
-31 -68 -63 -57 -50 -48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-29 -66 -60 -54 -47 -44
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 1.99 0.29 0.27 0.51 3.87
Price to Tangible Book Value (P/TBV)
0.00 1.99 0.29 0.27 0.51 3.87
Price to Revenue (P/Rev)
8.21 18.94 2.77 1.39 1.38 3.83
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
68.31 13.50 0.00 0.00 0.00 7.90
Enterprise Value to Revenue (EV/Rev)
16.39 10.18 0.00 0.00 0.00 3.25
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
1.00 0.00 0.00 0.00 0.00 0.57
Long-Term Debt to Equity
1.00 0.00 0.00 0.00 0.00 0.57
Financial Leverage
-0.84 -0.91 -0.89 -0.83 -0.75 -0.60
Leverage Ratio
2.82 1.27 1.12 1.18 1.25 1.59
Compound Leverage Factor
3.41 1.37 1.09 1.10 1.17 1.58
Debt to Total Capital
49.99% 0.00% 0.00% 0.00% 0.00% 36.27%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
49.99% 0.00% 0.00% 0.00% 0.00% 36.27%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
305.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-255.91% 100.00% 100.00% 100.00% 100.00% 63.73%
Debt to EBITDA
-0.85 0.00 0.00 0.00 0.00 -0.43
Net Debt to EBITDA
0.70 0.00 0.00 0.00 0.00 0.44
Long-Term Debt to EBITDA
-0.85 0.00 0.00 0.00 0.00 -0.43
Debt to NOPAT
-1.16 0.00 0.00 0.00 0.00 -0.57
Net Debt to NOPAT
0.95 0.00 0.00 0.00 0.00 0.58
Long-Term Debt to NOPAT
-1.16 0.00 0.00 0.00 0.00 -0.57
Altman Z-Score
-3.49 11.41 -1.94 -3.74 -6.38 -8.88
Noncontrolling Interest Sharing Ratio
611.71% 61.77% 0.00% 0.00% 0.00% 0.35%
Liquidity Ratios
- - - - - -
Current Ratio
4.00 12.01 7.27 6.34 4.61 3.31
Quick Ratio
3.22 10.93 5.99 5.14 3.32 2.24
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -47 -52 -37 -37 -17
Operating Cash Flow to CapEx
-4,492.17% -1,719.24% -868.65% -2,443.41% -3,234.65% -3,654.35%
Free Cash Flow to Firm to Interest Expense
0.00 -8.19 0.00 0.00 0.00 -15.97
Operating Cash Flow to Interest Expense
-4.88 -9.63 0.00 0.00 0.00 -28.50
Operating Cash Flow Less CapEx to Interest Expense
-4.98 -10.19 0.00 0.00 0.00 -29.28
Efficiency Ratios
- - - - - -
Asset Turnover
0.23 0.15 0.08 0.13 0.23 0.39
Accounts Receivable Turnover
3.22 4.65 3.30 4.13 4.30 6.31
Inventory Turnover
2.69 2.51 1.39 1.36 1.40 1.72
Fixed Asset Turnover
2.28 2.53 1.36 1.69 2.34 3.33
Accounts Payable Turnover
5.40 7.36 5.48 7.57 12.49 9.75
Days Sales Outstanding (DSO)
113.24 78.50 110.50 88.34 84.91 57.88
Days Inventory Outstanding (DIO)
135.51 145.16 262.01 268.16 260.28 211.96
Days Payable Outstanding (DPO)
67.53 49.57 66.62 48.23 29.22 37.43
Cash Conversion Cycle (CCC)
181.22 174.10 305.89 308.27 315.97 232.42
Capital & Investment Metrics
- - - - - -
Invested Capital
3.86 18 26 23 25 14
Invested Capital Turnover
4.17 2.17 0.79 0.92 1.18 1.55
Increase / (Decrease) in Invested Capital
0.00 14 8.21 -2.71 1.60 -16
Enterprise Value (EV)
264 237 -91 -64 -12 109
Market Capitalization
132 440 47 31 39 129
Book Value per Share
($354.19) $5.34 $3.91 $2.78 $1.75 $0.75
Tangible Book Value per Share
($354.19) $5.34 $3.91 $2.78 $1.75 $0.75
Total Capital
50 221 164 118 75 52
Total Debt
25 0.00 0.00 0.00 0.00 19
Total Long-Term Debt
25 0.00 0.00 0.00 0.00 19
Net Debt
-20 -203 -138 -95 -51 -19
Capital Expenditures (CapEx)
0.69 3.20 6.74 1.85 1.37 0.85
Debt-free, Cash-free Net Working Capital (DFCFNWC)
1.53 6.46 11 9.38 13 4.39
Debt-free Net Working Capital (DFNWC)
47 200 120 101 63 43
Net Working Capital (NWC)
47 200 120 101 63 43
Net Nonoperating Expense (NNE)
16 40 17 13 12 14
Net Nonoperating Obligations (NNO)
-21 -203 -138 -95 -51 -19
Total Depreciation and Amortization (D&A)
1.51 1.53 2.84 3.11 3.36 3.25
Debt-free, Cash-free Net Working Capital to Revenue
9.50% 27.81% 63.49% 41.64% 44.99% 13.06%
Debt-free Net Working Capital to Revenue
289.89% 860.70% 697.64% 450.42% 225.85% 127.08%
Net Working Capital to Revenue
289.89% 860.70% 697.64% 450.42% 225.85% 127.08%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($3.94) ($1.43) ($1.22) ($1.08) ($1.05)
Adjusted Weighted Average Basic Shares Outstanding
0.00 19.78M 42.45M 43.02M 43.58M 44.68M
Adjusted Diluted Earnings per Share
$0.00 ($3.94) ($1.43) ($1.22) ($1.08) ($1.05)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 19.78M 42.45M 43.02M 43.58M 44.68M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 41.94M 42.19M 42.50M 43.24M 45.46M
Normalized Net Operating Profit after Tax (NOPAT)
-21 -33 -44 -40 -35 -33
Normalized NOPAT Margin
-132.97% -142.31% -258.29% -175.83% -124.57% -98.77%
Pre Tax Income Margin
-229.79% -316.09% -358.27% -232.85% -167.08% -140.18%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
-4.81 -11.86 0.00 0.00 0.00 -43.58
NOPAT to Interest Expense
-3.36 -5.79 0.00 0.00 0.00 -30.44
EBIT Less CapEx to Interest Expense
-4.92 -12.43 0.00 0.00 0.00 -44.36
NOPAT Less CapEx to Interest Expense
-3.47 -6.35 0.00 0.00 0.00 -31.22
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Rapid Micro Biosystems

This table displays calculated financial ratios and metrics derived from Rapid Micro Biosystems' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
42,497,413.00 42,861,816.00 42,914,151.00 - 43,236,690.00 43,831,701.00 44,210,328.00 44,322,555.00 45,462,993.00 46,169,202.00 50,159,556.00
DEI Adjusted Shares Outstanding
42,497,413.00 42,861,816.00 42,914,151.00 - 43,236,690.00 43,831,701.00 44,210,328.00 44,322,555.00 45,462,993.00 46,169,202.00 50,159,556.00
DEI Earnings Per Adjusted Shares Outstanding
-0.31 -0.29 -0.26 - -0.26 -0.27 -0.26 -0.28 -0.31 -0.28 -0.22
Growth Metrics
- - - - - - - - - - -
Revenue Growth
11.44% 32.31% 23.74% 29.68% 28.41% 9.73% 3.08% 37.28% 11.06% 10.91% 21.56%
EBITDA Growth
4.45% 12.15% 18.07% 17.79% 19.51% 9.43% 5.10% -20.89% -20.52% -2.09% 6.02%
EBIT Growth
3.90% 11.15% 16.56% 16.02% 18.12% 8.98% 5.19% -18.35% -18.57% -1.53% 6.44%
NOPAT Growth
4.03% 11.13% 16.68% 16.07% 18.30% 9.19% 5.54% -19.38% -18.79% -1.43% 6.45%
Net Income Growth
4.07% 10.26% 15.45% 13.48% 15.46% 5.72% -1.61% -29.29% -26.74% -8.98% 2.06%
EPS Growth
3.13% 12.12% 16.13% 15.38% 16.13% 6.90% 0.00% -18.18% -19.23% 0.00% 11.54%
Operating Cash Flow Growth
6.96% -10.11% 11.41% -4.34% 41.61% 4.14% -5.24% 67.24% -66.11% -30.95% -49.78%
Free Cash Flow Firm Growth
65.74% 6.03% -64.32% -50.29% 8.63% -32.26% -26.17% 152.62% 57.37% 117.10% 72.48%
Invested Capital Growth
-12.83% -4.22% -1.00% 6.93% -9.79% 9.58% 10.08% -53.30% -30.73% -38.00% -17.77%
Revenue Q/Q Growth
-11.46% 17.95% 14.90% 8.07% -12.33% 0.79% 7.93% 43.94% -29.07% 0.65% 18.30%
EBITDA Q/Q Growth
-18.27% 6.84% 10.77% 16.38% -15.80% -4.71% 6.50% -6.52% -15.44% 11.30% 14.04%
EBIT Q/Q Growth
-17.18% 6.30% 9.87% 15.14% -14.24% -4.06% 6.12% -5.94% -14.45% 10.89% 13.41%
NOPAT Q/Q Growth
-17.11% 6.27% 10.01% 15.03% -14.00% -4.18% 6.39% -7.38% -13.44% 11.05% 13.66%
Net Income Q/Q Growth
-19.24% 5.58% 9.98% 14.63% -16.52% -5.28% 2.98% -8.62% -14.23% 9.47% 12.81%
EPS Q/Q Growth
-19.23% 6.45% 10.34% 15.38% -18.18% -3.85% 3.70% 0.00% -19.23% 12.90% 14.81%
Operating Cash Flow Q/Q Growth
-63.47% 34.82% 15.01% -15.22% 8.52% -7.01% 6.69% 64.14% -363.89% 15.65% -6.73%
Free Cash Flow Firm Q/Q Growth
-4.76% -35.27% 0.79% -6.90% 59.32% -95.79% 5.36% 169.82% -132.95% 178.56% -252.24%
Invested Capital Q/Q Growth
14.69% -4.57% -6.58% 4.58% -19.45% 15.92% -6.16% -46.70% 19.48% 3.75% 24.47%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
-27.14% -2.86% 8.18% 11.94% 5.61% 3.79% 8.88% -2.91% 4.64% 15.05% 25.21%
EBITDA Margin
-240.53% -189.98% -147.54% -114.15% -150.77% -156.80% -135.84% -100.52% -163.61% -144.19% -104.78%
Operating Margin
-254.38% -202.15% -158.32% -124.47% -161.85% -167.28% -145.09% -108.23% -173.11% -152.99% -111.66%
EBIT Margin
-254.89% -202.49% -158.84% -124.73% -162.53% -167.97% -146.10% -107.53% -173.51% -153.61% -112.44%
Profit (Net Income) Margin
-237.43% -190.06% -148.91% -117.62% -156.32% -163.29% -146.78% -110.77% -178.39% -160.45% -118.26%
Tax Burden Percent
100.02% 100.12% 100.11% 99.91% 100.06% 100.09% 100.07% 100.11% 100.06% 100.35% 100.19%
Interest Burden Percent
93.13% 93.75% 93.64% 94.39% 96.12% 97.12% 100.40% 102.90% 102.76% 104.09% 104.98%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-145.05% -135.77% -122.59% -102.60% -133.73% -134.31% -125.37% -117.30% -206.65% -168.42% -122.04%
ROIC Less NNEP Spread (ROIC-NNEP)
-141.75% -132.26% -119.07% -99.16% -128.62% -127.35% -116.42% -105.18% -186.56% -137.23% 7.08%
Return on Net Nonoperating Assets (RNNOA)
110.64% 103.17% 92.52% 74.72% 90.93% 82.25% 71.69% 63.15% 98.97% 52.31% -0.79%
Return on Equity (ROE)
-34.41% -32.60% -30.07% -27.87% -42.80% -52.06% -53.68% -54.16% -107.68% -116.11% -122.83%
Cash Return on Invested Capital (CROIC)
-124.46% -143.25% -152.49% -153.38% -121.56% -131.29% -138.15% -80.27% -135.85% -108.80% -125.84%
Operating Return on Assets (OROA)
-39.11% -35.99% -32.47% -28.96% -45.21% -52.81% -46.88% -41.75% -80.73% -80.63% -62.81%
Return on Assets (ROA)
-36.43% -33.78% -30.44% -27.31% -43.48% -51.34% -47.10% -43.01% -83.00% -84.22% -66.07%
Return on Common Equity (ROCE)
-34.41% -32.60% -30.07% -27.87% -42.80% -51.93% -53.51% -53.97% -107.68% -115.47% -121.91%
Return on Equity Simple (ROE_SIMPLE)
-48.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-9.99 -9.36 -8.43 -7.16 -8.16 -8.50 -7.96 -8.55 -9.70 -8.63 -7.45
NOPAT Margin
-178.06% -141.50% -110.83% -87.13% -113.29% -117.10% -101.56% -75.76% -121.17% -107.09% -78.16%
Net Nonoperating Expense Percent (NNEP)
-3.30% -3.52% -3.51% -3.44% -5.12% -6.97% -8.95% -12.12% -20.10% -31.19% -129.12%
Return On Investment Capital (ROIC_SIMPLE)
-9.43% -9.90% -9.99% -9.50% -12.46% -14.45% -11.85% -16.40% -24.58% -23.38% -26.57%
Cost of Revenue to Revenue
127.14% 102.86% 91.82% 88.06% 94.39% 96.21% 91.12% 102.91% 95.36% 84.95% 74.79%
SG&A Expenses to Revenue
100.29% 87.91% 74.64% 58.72% 78.97% 83.71% 72.01% 47.34% 93.00% 84.01% 66.44%
R&D to Revenue
68.47% 56.57% 47.46% 41.40% 50.30% 44.48% 45.02% 28.54% 41.98% 41.37% 31.17%
Operating Expenses to Revenue
227.23% 199.29% 166.50% 136.41% 167.45% 171.07% 153.97% 105.33% 177.74% 168.04% 136.87%
Earnings before Interest and Taxes (EBIT)
-14 -13 -12 -10 -12 -12 -11 -12 -14 -12 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-13 -13 -11 -9.38 -11 -11 -11 -11 -13 -12 -9.98
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.39 0.30 0.45 0.51 1.74 2.79 3.36 3.87 5.06 4.50 5.86
Price to Tangible Book Value (P/TBV)
0.39 0.30 0.45 0.51 1.74 2.79 3.36 3.87 5.06 4.50 5.86
Price to Revenue (P/Rev)
1.78 1.14 1.46 1.38 3.85 4.99 4.84 3.83 3.00 2.27 1.40
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 3.04 4.50 4.99 7.90 6.02 4.63 3.01
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 2.44 4.10 4.23 3.25 2.89 2.25 1.74
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.08 0.52 0.57 0.93 1.08 2.18
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.08 0.52 0.57 0.93 1.08 2.18
Financial Leverage
-0.78 -0.78 -0.78 -0.75 -0.71 -0.65 -0.62 -0.60 -0.53 -0.38 -0.11
Leverage Ratio
1.17 1.19 1.21 1.25 1.24 1.29 1.48 1.59 1.72 1.85 2.48
Compound Leverage Factor
1.08 1.11 1.13 1.18 1.20 1.25 1.48 1.64 1.77 1.93 2.61
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 7.35% 33.99% 36.27% 48.30% 51.89% 68.57%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 7.35% 33.99% 36.27% 48.30% 51.89% 68.57%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 91.98% 65.42% 63.73% 51.70% 48.11% 31.43%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.10 -0.54 -0.43 -0.41 -0.41 -0.42
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.63 0.44 0.44 0.08 0.01 -0.27
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.10 -0.54 -0.43 -0.41 -0.41 -0.42
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.13 -0.72 -0.57 -0.55 -0.55 -0.56
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.84 0.58 0.58 0.11 0.02 -0.36
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.13 -0.72 -0.57 -0.55 -0.55 -0.56
Altman Z-Score
-3.03 -4.01 -4.40 -5.04 -3.88 -4.36 -5.57 -7.32 -10.18 -11.51 -15.17
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.26% 0.31% 0.35% 0.00% 0.55% 0.75%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
6.93 5.92 5.52 4.61 4.61 3.67 4.23 3.31 2.57 2.55 2.20
Quick Ratio
5.41 4.48 4.06 3.32 3.08 2.27 2.82 2.24 1.53 1.39 0.87
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-6.10 -8.26 -8.19 -8.76 -5.58 -11 -10 7.21 -2.38 1.87 -2.84
Operating Cash Flow to CapEx
-2,653.85% -2,204.58% -3,856.50% -10,111.22% -2,841.69% -2,650.27% -12,398.63% -3,528.26% -3,821.83% 0.00% -27,114.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -744.57 0.00 -464.73 0.00 -26.29 0.00 -3.72 2.89 -4.50
Operating Cash Flow to Interest Expense
0.00 0.00 -781.82 0.00 -755.42 0.00 -23.03 0.00 -23.56 -19.66 -21.45
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -802.09 0.00 -782.00 0.00 -23.22 0.00 -24.18 -19.32 -21.53
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.15 0.18 0.20 0.23 0.28 0.31 0.32 0.39 0.47 0.52 0.56
Accounts Receivable Turnover
4.43 5.84 6.84 4.30 6.28 5.48 6.66 6.31 6.32 6.08 5.63
Inventory Turnover
1.37 1.33 1.32 1.40 1.35 1.33 1.33 1.72 1.75 1.68 1.63
Fixed Asset Turnover
1.77 1.95 2.14 2.34 2.56 2.70 2.89 3.33 3.56 3.83 4.30
Accounts Payable Turnover
23.10 15.93 9.80 12.49 14.65 10.16 9.51 9.75 9.14 7.81 7.89
Days Sales Outstanding (DSO)
82.43 62.53 53.33 84.91 58.13 66.63 54.83 57.88 57.79 59.99 64.84
Days Inventory Outstanding (DIO)
266.61 273.94 275.73 260.28 269.81 273.61 274.21 211.96 208.75 216.85 223.81
Days Payable Outstanding (DPO)
15.80 22.91 37.26 29.22 24.92 35.93 38.36 37.43 39.95 46.75 46.24
Cash Conversion Cycle (CCC)
333.24 313.57 291.80 315.97 303.02 304.31 290.67 232.42 226.59 230.09 242.41
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
26 25 24 25 24 28 26 14 17 17 21
Invested Capital Turnover
0.81 0.96 1.11 1.18 1.18 1.15 1.23 1.55 1.71 1.57 1.56
Increase / (Decrease) in Invested Capital
-3.89 -1.11 -0.24 1.60 -2.59 2.42 2.37 -16 -7.32 -10 -4.60
Enterprise Value (EV)
-38 -41 -23 -12 72 124 129 109 99 79 64
Market Capitalization
41 28 38 39 114 151 148 129 103 80 52
Book Value per Share
$2.49 $2.21 $1.97 $1.75 $1.51 $1.24 $0.99 $0.75 $0.45 $0.38 $0.18
Tangible Book Value per Share
$2.49 $2.21 $1.97 $1.75 $1.51 $1.24 $0.99 $0.75 $0.45 $0.38 $0.18
Total Capital
106 95 84 75 65 59 67 52 39 37 28
Total Debt
0.00 0.00 0.00 0.00 0.00 4.32 23 19 19 19 19
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 4.32 23 19 19 19 19
Net Debt
-80 -69 -61 -51 -42 -27 -18 -19 -3.90 -0.63 13
Capital Expenditures (CapEx)
0.59 0.46 0.22 0.10 0.32 0.37 0.07 0.09 0.39 -0.22 0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)
13 12 11 13 13 12 12 4.39 7.16 8.35 13
Debt-free Net Working Capital (DFNWC)
93 82 72 63 54 44 53 43 30 28 20
Net Working Capital (NWC)
93 82 72 63 54 44 53 43 30 28 20
Net Nonoperating Expense (NNE)
3.33 3.21 2.90 2.51 3.10 3.35 3.54 3.95 4.58 4.30 3.82
Net Nonoperating Obligations (NNO)
-80 -69 -61 -51 -42 -27 -18 -19 -3.90 -0.63 13
Total Depreciation and Amortization (D&A)
0.81 0.83 0.86 0.87 0.85 0.81 0.80 0.79 0.79 0.76 0.73
Debt-free, Cash-free Net Working Capital to Revenue
56.39% 49.40% 42.73% 44.99% 42.22% 41.23% 39.83% 13.06% 20.82% 23.73% 35.50%
Debt-free Net Working Capital to Revenue
400.78% 330.21% 275.18% 225.85% 182.78% 144.42% 174.96% 127.08% 87.56% 79.92% 53.74%
Net Working Capital to Revenue
400.78% 330.21% 275.18% 225.85% 182.78% 144.42% 174.96% 127.08% 87.56% 79.92% 53.74%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.31) ($0.29) ($0.26) ($0.22) ($0.26) ($0.27) ($0.26) ($0.26) ($0.31) ($0.27) ($0.23)
Adjusted Weighted Average Basic Shares Outstanding
43.25M 43.62M 43.67M 43.58M 43.99M 44.65M 44.96M 44.68M 45.43M 48.35M 48.88M
Adjusted Diluted Earnings per Share
($0.31) ($0.29) ($0.26) ($0.22) ($0.26) ($0.27) ($0.26) ($0.26) ($0.31) ($0.27) ($0.23)
Adjusted Weighted Average Diluted Shares Outstanding
43.25M 43.62M 43.67M 43.58M 43.99M 44.65M 44.96M 44.68M 45.43M 48.35M 48.88M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
42.86M 42.91M 43.03M 43.24M 43.83M 44.21M 44.32M 45.46M 46.17M 50.16M 50.84M
Normalized Net Operating Profit after Tax (NOPAT)
-9.99 -9.36 -8.43 -7.16 -8.16 -8.50 -7.96 -8.55 -9.70 -8.63 -6.94
Normalized NOPAT Margin
-178.06% -141.50% -110.83% -87.13% -113.29% -117.10% -101.56% -75.76% -121.17% -107.09% -72.87%
Pre Tax Income Margin
-237.37% -189.83% -148.74% -117.73% -156.22% -163.14% -146.68% -110.65% -178.29% -159.90% -118.04%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 -1,098.00 0.00 -975.83 0.00 -29.14 0.00 -21.73 -19.15 -16.95
NOPAT to Interest Expense
0.00 0.00 -766.12 0.00 -680.23 0.00 -20.26 0.00 -15.17 -13.35 -11.78
EBIT Less CapEx to Interest Expense
0.00 0.00 -1,118.27 0.00 -1,002.42 0.00 -29.32 0.00 -22.34 -18.81 -17.03
NOPAT Less CapEx to Interest Expense
0.00 0.00 -786.39 0.00 -706.81 0.00 -20.44 0.00 -15.79 -13.01 -11.86
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Rapid Micro Biosystems (NASDAQ: RPID) is showing revenue and gross-margin improvement, but it remains deeply unprofitable and heavily reliant on external financing and investment maturities to fund operations. The latest quarter suggests some progress in the core business, although the company’s cash burn and accumulated losses remain significant risks.

  • Revenue continued to grow. Q2 2026 revenue was $8.1 million, up approximately 11% from $7.3 million in Q2 2025 and above $8.0 million in Q1 2026. Revenue has generally moved higher from the $5.6 million reported in Q1 2024 and $6.1 million in Q3 2023.
  • Gross-margin performance improved materially. Gross profit increased to $1.2 million in Q2 2026 from $275,000 in Q2 2025 and a $328,000 gross loss in Q4 2025. The gross margin reached approximately 15%, compared with 4% in Q2 2025 and negative gross margins in several earlier quarters.
  • Quarterly net losses narrowed sequentially. The Q2 2026 net loss of $12.9 million improved from a $14.3 million loss in Q1 2026. The latest loss was also somewhat better than the $13.4 million loss in Q3 2023, although profitability remains well out of reach.
  • Liquidity remains supported by current assets. Rapid Micro Biosystems ended Q2 2026 with $14.7 million in cash and $5.1 million in short-term investments. Current assets of $46.3 million compared with current liabilities of $18.2 million, producing a current ratio of approximately 2.5.
  • Debt levels appear relatively stable. Long-term debt was $19.1 million at the end of Q2 2026, only modestly above $19.1 million in Q1 2026 and $18.8 million in Q3 2025. The company also reported no preferred stock and no commitments or contingencies in the supplied balance-sheet data.
  • Operating expenses remain elevated but showed mixed movement. Total operating expenses declined to $13.5 million in Q2 2026 from $14.2 million in Q1 2026, helped by lower selling, general and administrative expense. However, expenses remained above the $12.4 million reported in Q2 2025, and marketing and research-and-development costs continue to absorb substantial resources.
  • Investment activity has become an important source of liquidity. Investing cash flow was positive in Q2 2026 because $6.0 million of investments matured or were sold, more than offsetting purchases and capital expenditures. Similar investment sales supported cash flow in earlier quarters, so this benefit may not represent recurring operating cash generation.
  • Operating cash flow remains strongly negative. Cash used in operations was $12.7 million in Q2 2026, compared with $15.1 million in Q1 2026 and $9.7 million in Q2 2025. Operating cash flow has been negative in every supplied quarter, indicating that the business has not yet funded itself through customer revenue.
  • The company continues to report substantial recurring losses. Q2 2026 operating loss was $12.3 million and net loss was $12.9 million. The company has also accumulated retained earnings of negative $549.6 million, underscoring the long-running gap between revenue and the cost structure.
  • Equity financing is increasing dilution risk. Rapid Micro Biosystems raised $9.5 million through common-stock issuance in Q2 2026, compared with only $256,000 in Q1. Weighted-average basic shares rose to 48.3 million from 45.4 million in Q1 and 44.6 million in Q2 2025, or roughly 8% year over year.

Overall, the financial statements show a company making progress on revenue and gross margins, but not yet on profitability or self-sustaining cash generation. Q2’s $872,000 increase in cash was driven primarily by the $9.5 million equity raise and investment sales, rather than operating activities. Investors should watch whether gross-margin gains continue, whether operating expenses begin to decline relative to revenue, and how quickly cash and short-term investments are consumed without additional financing.

11/20/26 01:15 AM ETAI Generated. May Contain Errors.

Rapid Micro Biosystems Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Rapid Micro Biosystems' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Rapid Micro Biosystems' net income appears to be on an upward trend, with a most recent value of -$47.12 million in 2025, falling from -$37.08 million in 2020. The previous period was -$46.89 million in 2024. See Rapid Micro Biosystems' forecast for analyst expectations on what's next for the company.

Rapid Micro Biosystems' total operating income in 2025 was -$47.39 million, based on the following breakdown:
  • Total Gross Profit: $1.05 million
  • Total Operating Expenses: $48.44 million

Over the last 5 years, Rapid Micro Biosystems' total revenue changed from $16.08 million in 2020 to $33.59 million in 2025, a change of 108.9%.

In the past 12 quarters, Rapid Micro Biosystems' cash and equivalents has ranged from $6.62 million in Q3 2026 to $37.12 million in Q2 2024, and is currently $6.62 million as of their latest financial filing in Q3 2026.

Rapid Micro Biosystems had total debt of $18.90 million at the end of 2025, compared with none in 2024, and a 23.8% decrease since 2020.

Over the last 5 years, Rapid Micro Biosystems' book value per share changed from -354.19 in 2020 to 0.75 in 2025.



Financial statements for NASDAQ:RPID last updated on 11/19/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners